REGENXBIO Inc. stock is up 28.31% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 PUTs.
REGENXBIO Inc. provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells to produce therapeutic proteins or antibodies that are intended to impact disease. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.